What is HC Wainwright’s Forecast for Cingulate Q3 Earnings?

Cingulate Inc. (NASDAQ:CING) – Analysts at HC Wainwright issued their Q3 2026 earnings per share estimates for shares of Cingulate in a research note issued to investors on Tuesday, May 26th. HC Wainwright analyst R. Selvaraju forecasts that the company will post earnings per share of ($0.56) for the quarter. HC Wainwright has a “Buy” rating and a $20.00 price target on the stock. The consensus estimate for Cingulate’s current full-year earnings is ($2.44) per share. HC Wainwright also issued estimates for Cingulate’s FY2026 earnings at ($2.13) EPS.

A number of other analysts have also recently commented on the company. Wall Street Zen cut Cingulate from a “sell” rating to a “strong sell” rating in a research report on Saturday, May 16th. Ascendiant Capital Markets lowered their price target on Cingulate from $58.00 to $55.00 and set a “buy” rating for the company in a report on Wednesday, April 8th. Roth Mkm restated a “buy” rating and issued a $10.00 price target on shares of Cingulate in a report on Tuesday, May 19th. Finally, Weiss Ratings upgraded Cingulate from a “sell (e+)” rating to a “sell (d-)” rating in a report on Friday. Three equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, Cingulate has an average rating of “Moderate Buy” and a consensus price target of $28.33.

Cingulate Trading Up 6.9%

Cingulate stock opened at $4.78 on Wednesday. The stock has a market cap of $64.39 million, a PE ratio of -1.13 and a beta of -0.81. The stock has a 50-day moving average price of $5.79 and a 200 day moving average price of $5.34. Cingulate has a 52 week low of $3.20 and a 52 week high of $11.89.

Cingulate (NASDAQ:CING) last posted its quarterly earnings data on Thursday, May 14th. The company reported ($0.95) EPS for the quarter, missing analysts’ consensus estimates of ($0.53) by ($0.42).

Institutional Trading of Cingulate

Several hedge funds and other institutional investors have recently added to or reduced their stakes in CING. DRW Securities LLC purchased a new stake in Cingulate in the 4th quarter valued at about $255,000. Renaissance Technologies LLC purchased a new stake in Cingulate in the 1st quarter valued at about $198,000. Kestra Advisory Services LLC grew its holdings in Cingulate by 29.8% in the 4th quarter. Kestra Advisory Services LLC now owns 122,000 shares of the company’s stock valued at $529,000 after buying an additional 27,979 shares during the period. XTX Topco Ltd purchased a new stake in Cingulate in the 4th quarter valued at about $90,000. Finally, Chicago Partners Investment Group LLC purchased a new stake in Cingulate in the 1st quarter valued at about $116,000. Hedge funds and other institutional investors own 41.31% of the company’s stock.

Cingulate Company Profile

Cingulate Inc, a biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of attention deficit/hyperactivity disorder and anxiety in the United States. The company’s stimulant medications are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, as well as CTx-1302 (dextroamphetamine), which is in investigational new drug application development for the treatment of attention deficit/hyperactivity disorder intended for children, adolescents, and adults.